# Camp4 Therapeutics share price today (Camp4 Therapeutics Corporation, CAMP)

> Camp4 Therapeutics Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CAMP · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/camp

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.74 (−12.0% in a year)
- Revenue (Jun 2026): $1.8 M (+18.8% on a year ago)
- Profit (Jun 2026), incl. one-off: −$33.5 M (one-off item, see below)
- ROE: −169%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Camp4 Therapeutics share price today? Camp4 Therapeutics Corporation's share price was $3.74 at the close on 4 November 2026. That is 11.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $6, and at that close it sat 23% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 1 year the share price moved +149% while the S&P 500 moved +23%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Camp4 Therapeutics pay? Camp4 Therapeutics Corporation pays no dividend. In the last 8 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Camp4 Therapeutics on? Camp4 Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Camp4 Therapeutics profitable? Camp4 Therapeutics Corporation posted a net loss of $33.5 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $80.4 M. That loss is 1,884.8% of the quarter's revenue. The same quarter a year earlier lost $12.6 M. 8 of the last 8 reported quarters were loss-making. Read this profit with care: at −$33.5 M it is bigger than the quarter's whole revenue of $1.8 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −752.1% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Camp4 Therapeutics make, and is it growing? Camp4 Therapeutics Corporation reported $1.8 M of revenue in the Jun 2026 quarter, +18.8% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 2 years it has grown 216.1% a year on average. The last full year, FY25, came in at $3.5 M. The last four reported quarters add to $4.2 M. FY25 revenue was $3.5 M, +436.5% on the year before. Recent pace: the last four quarters grew +7.7% on average, against 216.1% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every $100 of sales does Camp4 Therapeutics keep? Camp4 Therapeutics Corporation has almost no sales yet: FY25 revenue was $3.5 M. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Camp4 Therapeutics' profit turning into cash? Camp4 Therapeutics Corporation's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $29.6 M of cash, against −$80.4 M of profit. After $279 K of spending on assets, free cash was −$29.8 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Camp4 Therapeutics' cash go? Camp4 Therapeutics Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.4 M on assets over the last 3 years. Averaged over those years that is 13.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.4 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Camp4 Therapeutics' P/E ratio, and how does it compare with its own history? Camp4 Therapeutics Corporation has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Camp4 Therapeutics Corporation at 67.1× its FY25 revenue of $3.5 M. The P/E comes back here once profit turns positive. ## Is the Camp4 Therapeutics business getting better or worse? Camp4 Therapeutics Corporation's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Camp4 Therapeutics earn on its capital? Camp4 Therapeutics Corporation earned a ROE of −169% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −134%, a number that says nothing useful about the business. ## Does Camp4 Therapeutics have too much debt? Camp4 Therapeutics Corporation's net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 0.15 in FY22 to 0.04 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Camp4 Therapeutics shareholding pattern? 8.0% of Camp4 Therapeutics Corporation's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 11.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Camp4 Therapeutics from balance-sheet trouble? For Camp4 Therapeutics Corporation, the Z-score is −4.90. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −4.90 is inside the danger zone, so the balance sheet is a real risk. ## How does Camp4 Therapeutics rank in its industry? There is no score against its industry: Camp4 Therapeutics Corporation is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Camp4 Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Camp4 Therapeutics in size? Camp4 Therapeutics is the 185th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Korro Bio, Inc., Immuneering Corporation and Abeona Therapeutics Inc. Just below it: Vanda Pharmaceuticals Inc., AC Immune SA and Evommune, Inc. ### Biotechnology companies close in size

1. [Korro Bio, Inc.](https://www.sectoralpha.in/us/stocks/krro) $245 million
2. [Immuneering Corporation](https://www.sectoralpha.in/us/stocks/imrx) $244 million
3. [Abeona Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/abeo) $241 million
4. Camp4 Therapeutics Corporation $235 million
5. [Vanda Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/vnda) $235 million
6. [AC Immune SA](https://www.sectoralpha.in/us/stocks/aciu) $228 million
7. [Evommune, Inc.](https://www.sectoralpha.in/us/stocks/evmn) $219 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [TechTarget, Inc.](https://www.sectoralpha.in/us/stocks/ttgt) $242 million · Information Technology Services
2. [Perma-Pipe International Holdings, Inc.](https://www.sectoralpha.in/us/stocks/ppih) $241 million · Building Products & Equipment
3. Camp4 Therapeutics Corporation $240 million
4. [Security National Financial Corporation](https://www.sectoralpha.in/us/stocks/snfca) $240 million · Insurance - Life
5. [Standard BioTools Inc.](https://www.sectoralpha.in/us/stocks/lab) $240 million · Medical Devices

## What else do people ask about Camp4 Therapeutics? ### What were Camp4 Therapeutics's latest quarterly results? Camp4 Therapeutics Corporation reported revenue of $1.8 M and a net loss of $33.5 M for the Jun 2026 quarter. Earnings per share were −$0.58. The operating margin was −752.1%, 118.2 percentage points higher than a year earlier (as of 4 November 2026). ### What is Camp4 Therapeutics's market cap? Camp4 Therapeutics Corporation's market capitalisation is $235 M at a stock price of $3.74. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Camp4 Therapeutics performing? Camp4 Therapeutics Corporation's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Camp4 Therapeutics's stock price go up? This page does not forecast Camp4 Therapeutics Corporation's stock price. What it shows instead: the stock price is $3.74. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Does Camp4 Therapeutics have too much debt? No, Camp4 Therapeutics Corporation has little debt: its debt is 0.07× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### What could break the Camp4 Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Camp4 Therapeutics a stock worth studying right now? What the numbers show: Camp4 Therapeutics Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.